Comprehensive updates on the treatment of esophageal and gastric cancer emphasize the crucial role of perioperative systemic therapy. Neoadjuvant chemoradiotherapy followed by postoperative immunotherapy is standard for locally advanced squamous cell carcinoma, while perioperative FLOT chemotherapy shows superior outcomes for adenocarcinoma. Promising results are also noted for MSI-high tumor patients receiving neoadjuvant immunotherapy. The focus on prehabilitation and specialized care aims to lower the high cancer-specific mortality rates, which currently reach 70%.
Review by Lordick Obermannová R, Jedlička V (…) Kiss I et 6 al. in Rozhl Chir